EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Novel Human Interleukin‐23A Overexpressing Mouse Model of Systemic Lupus Erythematosus

Eleni Christodoulou-Vafeiadou, Christina Geka, Lida Iliopoulou, Lydia Ntari, Maria C Denis, Niki Karagianni, George Kollias iD

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Eleni Christodoulou-Vafeiadou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biomedcode Hellas SA, Athens, Greece. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Disease Models, Animal, Mice, Transgenic, Interleukin-23 Subunit p19. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biomedical Sciences Research Center (BSRC) Alexander Fleming's Transgenics and Flow Cytometry facilities, InfrafrontierGR/Phenotypos Infrastructure, Operational Programme "Competitiveness, Entrepreneurship and Innovation".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Interleukin‐23 (IL‐23) is a crucial cytokine implicated in chronic inflammation and autoimmunity, associated with various diseases such as psoriasis, psoriatic arthritis, and systemic lupus erythematosus (SLE). This study aimed to create and characterize a transgenic mouse model overexpressing human IL‐23A (TghIL‐23A), providing a valuable tool for investigating the pathogenic role of human IL‐23A and evaluating the efficacy of anti–human IL‐23A therapeutics.

Methods

TghIL‐23A mice were generated via microinjection of CBA × C57BL/6 zygotes with a fragment of the human IL23A gene, flanked by its 5′‐regulatory sequences and the 3′ untranslated region of human β‐globin. The TghIL‐23A pathology was assessed through hematologic and biochemic analyses, cytokine and antinuclear antibody detection, and histopathologic examination of skin and renal tissues. The response to the anti–human IL‐23A therapeutic agent guselkumab was evaluated in groups of eight mixed‐sex mice receiving subcutaneous treatment twice weekly for 10 weeks using clinical, biomarker, and histopathologic readouts.

Results

TghIL‐23A mice exhibited interactions between human IL‐23A and mouse IL‐23/IL‐12p40 and developed a chronic multiorgan autoimmune disease marked by proteinuria, anti–double‐stranded DNA antibodies, severe inflammatory lesions in the skin, and milder phenotypes in the kidneys and lungs. The TghIL‐23A pathologic features exhibited significant similarities to those observed in human patients with SLE, and they were reversed following guselkumab treatment.

Conclusion

We have generated and characterized a novel genetic mouse model of SLE, providing proof‐of‐concept for the etiopathogenic role of human IL‐23A. This new model has a normal life span and integrates several characteristics of the human disease's complexity and chronicity, making it an attractive preclinical tool for studying IL‐23–dependent pathogenic mechanisms and assessing the efficacy of anti–human IL‐23A or modeled disease‐related therapeutics. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicDisease Models, AnimalMice, TransgenicInterleukin-23 Subunit p19AnimalsMiceHumansFemaleAntibodies, Monoclonal, HumanizedMice, Inbred C57BLMaleAntibodies, AntinuclearMice, Inbred CBA

Substanzen

Interleukin-23 Subunit p19Antibodies, Monoclonal, HumanizedIL23A protein, humanAntibodies, Antinuclear

Autor:innen und Institutionen

  • Biomedcode Hellas SA, Athens, Greece.
  • Biomedical Sciences Research Center (BSRC) Alexander Fleming, Athens, Greece.
  • BSRC Alexander Fleming, Athens, Greece, and School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: George Kollias

Förderung

  • Biomedical Sciences Research Center (BSRC) Alexander Fleming's Transgenics and Flow Cytometry facilities
  • InfrafrontierGR/Phenotypos Infrastructure
  • Operational Programme "Competitiveness, Entrepreneurship and Innovation"
  • RESEARCH-CREATE-INNOVATE
  • European Regional Development Fund of the European Union

Zitieren

APA

Christodoulou-Vafeiadou, E., Geka, C., Iliopoulou, L., Ntari, L., Denis, M. C., Karagianni, N., & Kollias, G. (2024). A Novel Human Interleukin‐23A Overexpressing Mouse Model of Systemic Lupus Erythematosus. Arthritis & Rheumatology. https://doi.org/10.1002/art.42830

Vancouver

Christodoulou-Vafeiadou E, Geka C, Iliopoulou L, Ntari L, Denis MC, Karagianni N, et al. A Novel Human Interleukin‐23A Overexpressing Mouse Model of Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2024. doi:10.1002/art.42830

BibTeX
@article{ChristodoulouVafeiadou2024,
  author = {Christodoulou-Vafeiadou, Eleni and Geka, Christina and Iliopoulou, Lida and Ntari, Lydia and Denis, Maria C and Karagianni, Niki and Kollias, George},
  title = {A Novel Human Interleukin‐23A Overexpressing Mouse Model of Systemic Lupus Erythematosus},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42830}
}
Kostenlos starten →